Streamline Your mAb Manufacturing With Strategic Development And CDMO Compatibility

By Robin Dothager, Senior Manager of Process Development; Jing Huang, Supervisor, Process Development; Henry Hymas, Supervisor, Process Development; and Buzz Lobbezoo, Senior Field Application Scientist

Monoclonal antibodies, bispecific antibodies, and antibody drug conjugates are widely regarded for their ability to provide highly personalized treatments for cancer, autoimmune disorders, central nervous system conditions, and metabolic indications. Their unique capabilities have resulted in their rapid expansion across the pharmaceutical industry. For mAb developers looking to embark on a fruitful CDMO partnership, it is critical to consider how best to design a mAb production process that can be easily scalable to 2,000 L and beyond.

Though the earliest phases of mAb development begin at lab scale where complex workflows are manageable, attempting to execute elaborate processes at large-scale for commercial manufacturing can lead to major challenges during tech transfer and scale-up with a CDMO. To mitigate these potential challenges, consider how best to tailor your mAb process to facilitate scalability. Download the full whitepaper to explore how a well-designed mAb workflow can increase speed to market and enable cost savings while providing a high-quality product for patients.